Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Yemen
ACTRN12617000283370Phase 4Completed
- Sponsor
- Haiti Ministry of Public Health and Population
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artemether and lumefantrine in malaria and Falciparum malaria (PF), sponsored by Haiti Ministry of Public Health and Population. Primary endpoints: Percent of treatment failures and Adequate clinical and parasitological response. Started Dec 2019; status: completed.
02
Drugs
artemetherlumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12617000283370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000283370.